Trump’s New Contract Aims to Reform Drug Pricing

President Donald Trump has unveiled a significant new contract aimed at reforming the pharmaceutical industry and reducing drug prices for consumers.

He mentioned a substantial discount for Pfizer on some of its “most popular drugs,” and stated that all new drugs launched in the U.S. will be priced in line with “preferred countries,” which is intended to lower costs. Additionally, he announced that these drugs will be available for purchase through the federally managed “Trumprx” consumer website.

“The big winner of this contract will obviously be the American patient,” Trump remarked.

He emphasized, “This will significantly impact Medicaid costs,” during a statement he made in the Oval Office earlier this week.

Spokesperson Caroline Leavitt expressed that “this is a consequential moment for our country,” adding that drug prices for ordinary Americans have been lowered due to Trump’s negotiations. She also pointed out that Democrats have been trying to achieve this for decades, and that the Trump administration has finally made it happen.

In May, Trump issued a Presidential Order directing pharmaceutical companies to adopt “most preferred country” prices for American patients. If they do not comply, the Department of Health and Human Services will establish rules to enforce this policy, and the Food and Drug Administration could revoke approvals for drugs deemed “unsafe, ineffective, or improperly marketed.”

Trump also reached out to over a dozen Major Pharmaceutical CEOs, demanding that they voluntarily extend “most preferred country” pricing to all drugs supplied to Medicaid beneficiaries, giving them a deadline for response until Monday.

“If we don’t get cooperation, we will utilize every tool at our disposal to protect American families from ongoing abusive drug pricing practices,” Trump warned.

Interestingly, Eli Lilly has vowed to raise prices in Europe to offset costs in the U.S., and Bristol-Myers Squibb is aligning its list price for new schizophrenia treatments in both the U.S. and the U.K.

Pfizer’s CEO, Albert Bourla, also stated at a press conference, “There is no doubt that the American patient will benefit immensely from this contract, which will greatly enhance their ability to afford medication.”